Loading…

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors

Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze th...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2019-06, Vol.19 (1), p.575-575, Article 575
Main Authors: Bösch, Florian, Bazhin, Alexandr V, Heublein, Sabine, Brüwer, Katharina, Knösel, Thomas, Reiter, Florian P, Auernhammer, Christoph J, Guba, Markus O, Spitzweg, Christine, Werner, Jens, Angele, Martin K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33
cites cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33
container_end_page 575
container_issue 1
container_start_page 575
container_title BMC cancer
container_volume 19
creator Bösch, Florian
Bazhin, Alexandr V
Heublein, Sabine
Brüwer, Katharina
Knösel, Thomas
Reiter, Florian P
Auernhammer, Christoph J
Guba, Markus O
Spitzweg, Christine
Werner, Jens
Angele, Martin K
description Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs. Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study. Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis. This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.
doi_str_mv 10.1186/s12885-019-5794-y
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A590758869</galeid><doaj_id>oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c</doaj_id><sourcerecordid>A590758869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rr6A7yRgiB60TVfbdMbYVn8GFgQdL0Op8lpJ0PbjEmqO_f-cDM76zoV6UXT9HmfktM3y55Tck6prN4GyqQsC0KboqwbUeweZKdU1LRggtQPj9Yn2ZMQNoTQWhL5ODvhlDYVZfVp9uvaI8QRp5j_tHGdBzdCdCFCtFMOEwyuD7mdzKwx5MZ2HfrEWhiGXY43W48hoMkHjEWti3KbIiYfrS845XXK5WFMaFpEDMmI-YSzdzgZp_3-Mc6j8-Fp9qiDIeCzu_tZ9u3D--vLT8XV54-ry4urQlesjAVtWWNazQhK1lBJyopWlWacGwmEl6ainDEExIY1mnDW1a2GRohWgJaInJ9lq4PXONiorbcj-J1yYNXthvO9Ah-tHlC1HUBJKs4BhaBEy6pJKtkKJgwIqpPr3cG1ndsRjU5T8TAspMs3k12r3v1QVVnVyZIEr-8E3n2f03jUaIPGYYAJ3RwUY4JJymlTJvTlP-jGzT79nFuKMyEp4X-pHtIB7NS59F29l6qLsiF1KdMhEnX-HypdBker3YSdTfuLwJtFIDERb2IPcwhq9fXLkn11xK4RhrgObpijdVNYgvQAau9C8NjdD44Ste-2OnRbpW6rfbfVLmVeHE_8PvGnzPw39V_z9g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243248103</pqid></control><display><type>article</type><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</creator><creatorcontrib>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</creatorcontrib><description>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs. Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study. Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis. This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-019-5794-y</identifier><identifier>PMID: 31196127</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Apoptosis ; Biological Variation, Population ; Biomarkers ; Breast cancer ; Cancer metastasis ; Care and treatment ; Cell growth ; Colorectal cancer ; Female ; Gene expression ; Gene Expression Profiling ; Humans ; Intestinal Neoplasms - drug therapy ; Intestine, Small - pathology ; Intra-individual ; Kinases ; Liver ; Lung cancer ; Lymphatic system ; Male ; Medical research ; Metastases ; Metastasis ; MicroRNA ; MicroRNAs ; MicroRNAs - genetics ; Middle Aged ; Neuroendocrine tumor ; Neuroendocrine tumors ; Neuroendocrine Tumors - drug therapy ; Patients ; Prospective Studies ; Ribonucleic acid ; RNA ; Small intestine ; Somatostatin ; Somatostatin - analogs &amp; derivatives ; Somatostatin - therapeutic use ; Surgery ; Tumors</subject><ispartof>BMC cancer, 2019-06, Vol.19 (1), p.575-575, Article 575</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</citedby><cites>FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</cites><orcidid>0000-0002-0250-9017</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567424/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2243248103?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31196127$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bösch, Florian</creatorcontrib><creatorcontrib>Bazhin, Alexandr V</creatorcontrib><creatorcontrib>Heublein, Sabine</creatorcontrib><creatorcontrib>Brüwer, Katharina</creatorcontrib><creatorcontrib>Knösel, Thomas</creatorcontrib><creatorcontrib>Reiter, Florian P</creatorcontrib><creatorcontrib>Auernhammer, Christoph J</creatorcontrib><creatorcontrib>Guba, Markus O</creatorcontrib><creatorcontrib>Spitzweg, Christine</creatorcontrib><creatorcontrib>Werner, Jens</creatorcontrib><creatorcontrib>Angele, Martin K</creatorcontrib><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs. Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study. Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis. This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis</subject><subject>Biological Variation, Population</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer metastasis</subject><subject>Care and treatment</subject><subject>Cell growth</subject><subject>Colorectal cancer</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Intestinal Neoplasms - drug therapy</subject><subject>Intestine, Small - pathology</subject><subject>Intra-individual</subject><subject>Kinases</subject><subject>Liver</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>MicroRNA</subject><subject>MicroRNAs</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>Neuroendocrine tumor</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Small intestine</subject><subject>Somatostatin</subject><subject>Somatostatin - analogs &amp; derivatives</subject><subject>Somatostatin - therapeutic use</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7rr6A7yRgiB60TVfbdMbYVn8GFgQdL0Op8lpJ0PbjEmqO_f-cDM76zoV6UXT9HmfktM3y55Tck6prN4GyqQsC0KboqwbUeweZKdU1LRggtQPj9Yn2ZMQNoTQWhL5ODvhlDYVZfVp9uvaI8QRp5j_tHGdBzdCdCFCtFMOEwyuD7mdzKwx5MZ2HfrEWhiGXY43W48hoMkHjEWti3KbIiYfrS845XXK5WFMaFpEDMmI-YSzdzgZp_3-Mc6j8-Fp9qiDIeCzu_tZ9u3D--vLT8XV54-ry4urQlesjAVtWWNazQhK1lBJyopWlWacGwmEl6ainDEExIY1mnDW1a2GRohWgJaInJ9lq4PXONiorbcj-J1yYNXthvO9Ah-tHlC1HUBJKs4BhaBEy6pJKtkKJgwIqpPr3cG1ndsRjU5T8TAspMs3k12r3v1QVVnVyZIEr-8E3n2f03jUaIPGYYAJ3RwUY4JJymlTJvTlP-jGzT79nFuKMyEp4X-pHtIB7NS59F29l6qLsiF1KdMhEnX-HypdBker3YSdTfuLwJtFIDERb2IPcwhq9fXLkn11xK4RhrgObpijdVNYgvQAau9C8NjdD44Ste-2OnRbpW6rfbfVLmVeHE_8PvGnzPw39V_z9g</recordid><startdate>20190613</startdate><enddate>20190613</enddate><creator>Bösch, Florian</creator><creator>Bazhin, Alexandr V</creator><creator>Heublein, Sabine</creator><creator>Brüwer, Katharina</creator><creator>Knösel, Thomas</creator><creator>Reiter, Florian P</creator><creator>Auernhammer, Christoph J</creator><creator>Guba, Markus O</creator><creator>Spitzweg, Christine</creator><creator>Werner, Jens</creator><creator>Angele, Martin K</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0250-9017</orcidid></search><sort><creationdate>20190613</creationdate><title>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</title><author>Bösch, Florian ; Bazhin, Alexandr V ; Heublein, Sabine ; Brüwer, Katharina ; Knösel, Thomas ; Reiter, Florian P ; Auernhammer, Christoph J ; Guba, Markus O ; Spitzweg, Christine ; Werner, Jens ; Angele, Martin K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis</topic><topic>Biological Variation, Population</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer metastasis</topic><topic>Care and treatment</topic><topic>Cell growth</topic><topic>Colorectal cancer</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Intestinal Neoplasms - drug therapy</topic><topic>Intestine, Small - pathology</topic><topic>Intra-individual</topic><topic>Kinases</topic><topic>Liver</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>MicroRNA</topic><topic>MicroRNAs</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>Neuroendocrine tumor</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Small intestine</topic><topic>Somatostatin</topic><topic>Somatostatin - analogs &amp; derivatives</topic><topic>Somatostatin - therapeutic use</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bösch, Florian</creatorcontrib><creatorcontrib>Bazhin, Alexandr V</creatorcontrib><creatorcontrib>Heublein, Sabine</creatorcontrib><creatorcontrib>Brüwer, Katharina</creatorcontrib><creatorcontrib>Knösel, Thomas</creatorcontrib><creatorcontrib>Reiter, Florian P</creatorcontrib><creatorcontrib>Auernhammer, Christoph J</creatorcontrib><creatorcontrib>Guba, Markus O</creatorcontrib><creatorcontrib>Spitzweg, Christine</creatorcontrib><creatorcontrib>Werner, Jens</creatorcontrib><creatorcontrib>Angele, Martin K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bösch, Florian</au><au>Bazhin, Alexandr V</au><au>Heublein, Sabine</au><au>Brüwer, Katharina</au><au>Knösel, Thomas</au><au>Reiter, Florian P</au><au>Auernhammer, Christoph J</au><au>Guba, Markus O</au><au>Spitzweg, Christine</au><au>Werner, Jens</au><au>Angele, Martin K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2019-06-13</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>575</spage><epage>575</epage><pages>575-575</pages><artnum>575</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Distant metastases frequently occur in gastroenteropancreatic neuroendocrine tumors. If hepatic surgery is not feasible, patients are treated with somatostatin analogs. However, the underlying mechanisms of action of this treatment remain to be defined. The aim of the present study was to analyze the micro-RNA expression profile inter-individually before and after the treatment with somatostatin analogs. Tumor specimens of all included patients (n = 8) before and after the onset of a therapy with somatostatin analogs were analyzed and a micro-RNA expression profile (754 micro-RNAs) of each probe was generated. This analysis in an intra-individual setting was selected to avoid bias from inter-individual differences. The micro-RNA expression profiles were validated by qPCR. Patients with any other systemic treatment were excluded from the present study. Eight patients were included in the present study of which all had neuroendocrine tumors of the small intestine with diffuse hepatic metastases. Grouped analyses revealed that 15 micro-RNAs were differentially expressed (3 up- and 12 downregulated) after the exposure to somatostatin analogs. Additionally, let-7c-5p and mir-3137 are concordantly regulated in the inter-individually analysis. This is the first study analyzing the individual micro-RNA expression profile before and after a therapy with somatostatin analogs. Data from this study reveal that somatostatin analogs may in part exert their beneficial effects through an alteration in the micro-RNA expression profile.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31196127</pmid><doi>10.1186/s12885-019-5794-y</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0250-9017</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2019-06, Vol.19 (1), p.575-575, Article 575
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_bfaa50633ae4410c869a948b424da41c
source Publicly Available Content Database; PubMed Central
subjects Aged
Antineoplastic Agents - therapeutic use
Apoptosis
Biological Variation, Population
Biomarkers
Breast cancer
Cancer metastasis
Care and treatment
Cell growth
Colorectal cancer
Female
Gene expression
Gene Expression Profiling
Humans
Intestinal Neoplasms - drug therapy
Intestine, Small - pathology
Intra-individual
Kinases
Liver
Lung cancer
Lymphatic system
Male
Medical research
Metastases
Metastasis
MicroRNA
MicroRNAs
MicroRNAs - genetics
Middle Aged
Neuroendocrine tumor
Neuroendocrine tumors
Neuroendocrine Tumors - drug therapy
Patients
Prospective Studies
Ribonucleic acid
RNA
Small intestine
Somatostatin
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Surgery
Tumors
title Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A32%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20with%20somatostatin%20analogs%20induces%20differentially%20expressed%20let-7c-5p%20and%20mir-3137%20in%20small%20intestine%20neuroendocrine%20tumors&rft.jtitle=BMC%20cancer&rft.au=B%C3%B6sch,%20Florian&rft.date=2019-06-13&rft.volume=19&rft.issue=1&rft.spage=575&rft.epage=575&rft.pages=575-575&rft.artnum=575&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-019-5794-y&rft_dat=%3Cgale_doaj_%3EA590758869%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-1b29dbc20e82918056166c233d8a035d61322eaee929c032f7bca944b4ac8ee33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2243248103&rft_id=info:pmid/31196127&rft_galeid=A590758869&rfr_iscdi=true